Bio-Rad Laboratories Director Receives Annual Equity Award and Settles RSUs
BIO-RAD LABORATORIES, INC.
Subscribe to track BIO
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
BIO-RAD LABORATORIES, INC. ($BIO) - Form 4 Filing
Insider: Allison Schwartz (Director)
Filing Date: September 9, 2026
Summary of Activity:
- Granted 719 Restricted Stock Units (RSUs) on 09/04/2026.
- Vested 320 total RSUs across 09/05 and 09/06.
- Surrendered 116 shares for tax withholding at $386.11/share ($44,788.76 total).
- Direct Common Stock Ownership Post-Transactions: 1,734 shares.
Comprehensive Analysis
Insider Filing Analysis: Bio-Rad Laboratories, Inc. ($BIO)
Transaction Overview
On September 9, 2026, Director Allison Schwartz filed a Form 4 disclosing routine equity compensation events:
- RSU Award Grant (Sept 4, 2026): Received an award of 719 Restricted Stock Units (RSUs), vesting over four years (25% on the first anniversary and quarterly thereafter).
- RSU Vesting & Conversion (Sept 5–6, 2026): Acquired 228 Class A common shares on September 5 and 92 Class A common shares on September 6 upon the vesting of previously granted RSUs.
- Tax Withholding (Sept 5–6, 2026): Disposed of 82 shares on September 5 and 34 shares on September 6 at $386.11 per share to cover statutory tax withholding liabilities resulting from the vesting.
Post-Transaction Holdings
Following these transactions, Allison Schwartz directly holds:
- 1,734 shares of Bio-Rad Class A Common Stock.
- Multiple remaining unvested RSU tranches.
Market Significance
This filing reflects standard director compensation and routine tax-withholding settlements. Because no open-market purchases or discretionary sales took place, this activity carries Low informational significance for market direction.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.